إعلان
إعلان

CADL

CADL logo

Candel Therapeutics, Inc. Common Stock

5.71
USD
برعاية
+0.15
+2.70%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

قبل الإفتتاح

5.69

-0.02
-0.33%

تقارير أرباح CADL

النسبة الإيجابية المفاجئة

CADL تفوق 8 من 15 آخر التقديرات.

53%

التقرير التالي

بيانات التقرير القادم
٢٣ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.25
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+19.05%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-37.50%

Candel Therapeutics, Inc. Common Stock earnings per share and revenue

On ١٣ نوفمبر ٢٠٢٥, CADL reported earnings of -0.21 USD per share (EPS) for Q3 25, missing the estimate of -0.18 USD, resulting in a -11.23% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.30% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 المحللين forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an زيادة of 19.05% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Candel Therapeutics, Inc. Common Stock reported EPS of -$0.21, missing estimates by -11.23%, and revenue of $0.00, 0% as expectations.
The stock price moved down -6.3%, changed from $4.92 before the earnings release to $4.61 the day after.
The next earning report is scheduled for ٢٣ مارس ٢٠٢٦.
Based on 9 المحللين, Candel Therapeutics, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان